| Ytd | -21.48% | |
| 1y | -24.29% |
| Open | 1.02 | Prev Close | 1.03 | Low | 1.00 | High | 1.08 | Mkt Cap | 359.46M |
| Vol | 14.76M | Avg Vol | 6.84M | EPS | -0.26 | P/E | N/A | Forward P/E | -2.85 |
| Beta | 3.77 | Short Ratio | 14.01 | Inst. Own | 27.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 1.29 | 200-d Avg | 1.51 | 1yr Est | 6.25 |
Ocugen NASDAQ: OCGN is preparing for three planned biologics license application, or BLA, submission
Ocugen is advancing three gene therapy programs—OCU400, OCU410ST, and OCU410—targeting major unmet n
Shares of Ocugen are remaining flat Thursday morning as investors continue to weigh disappointing in
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula
Ocugen moves OCU410 into phase III for geographic atrophy, with FDA-aligned study plans. The company
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in g
MALVERN, Pa., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: O
MALVERN, Pa., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),
Shares of Ocugen, Inc. (NASDAQ: OCGN - Get Free Report) have earned a consensus rating of "Moderate
Ocugen NASDAQ: OCGN is positioning its ophthalmology gene therapy portfolio around treatments for in
OCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs
Ocugen NASDAQ: OCGN said its second quarter marked progress across its late-stage ophthalmology pipe
Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript
Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consens
Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) c
MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN),
RMAT designation is intended to help expedite development of new regenerative medicines that have po
MALVERN, Pa, July 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCG
MALVERN, Pa. , July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRo
Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones R
Ocugen NASDAQ: OCGN outlined plans to advance three late-stage retinal disease programs, with compan
MALVERN, Pa. , July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN)
Canaccord Genuity analyst Whitney Ijem maintains Ocugen (NASDAQ:OCGN) with a Buy and lowers the p
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which missed the analyst consens
Dow futures up 100 pts. Shares of GeneDx Holdings (WGS) down 39.2% after cutting FY26 sales guidance
Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a pioneering biotechnology l
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Ocugen (NASDAQ:OCGN) with a Buy
Ocugen stock falls after Phase 2 OCU410 data for dry AMD trails interim results, despite lesion redu
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth
Canaccord Genuity analyst Whitney Ijem initiates coverage on Ocugen (NASDAQ:OCGN) with a Buy rati
Ocugen shares are surging Wednesday afternoon after Oppenheimer analyst Leland Gershell initiated co
Dow falls 200+ points as Serve Robotics Inc (NASDAQ: SERV) shares rise 16.2% on better-than-expected
Top Wall Street analysts changed outlook on top names. For all analyst rating changes, see analyst r
Oppenheimer analyst Leland Gershell initiates coverage on Ocugen (NASDAQ:OCGN) with a Outperform
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.06) per share which met the analyst consensus
Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a pioneering biotechnology leader in gene therap
Ocugen shares sank sharply Wednesday after the biotech company announces a $22.5 million underwritte
Ocugen Inc (NASDAQ:OCGN) shares are up on Friday as the company is gaining traction following positi